10-K: Protagenic Therapeutics Outlines Share Structure and Business Strategy in Annual Filing

Protagenic Therapeutics' annual 10-K filing details its capital structure, ongoing clinical trials, and strategic focus on developing treatments for stress-related neuropsychiatric disorders.

Summary

• Protagenic Therapeutics is a biopharmaceutical company focused on developing treatments for stress-related neuropsychiatric and mood disorders.
• Their lead compound, PT00114, is a synthetic form of TCAP, a brain signaling peptide that can reduce overactive stress responses.
• As of March 31, 2023, there were 4,321,445 shares of common stock outstanding and 0 shares of Series B Preferred Stock outstanding.
• The company has commenced its first human trial for PT00114 on September 26, 2023, and anticipates announcing complete results of the single-dose portion in the second quarter of 2024.
• Protagenic is also developing additional product candidates from the TCAP family and exploring efficacy in other stress-related disorders.
• The company is targeting treatment-resistant depression, substance use disorder, generalized anxiety disorder, and post-traumatic stress disorder.
• The company has completed preclinical experiments and is currently in Phase I/II clinical trials.
• The company has a license agreement with the University of Toronto for exclusive worldwide rights to PT00114.
• The company has never paid cash dividends and does not anticipate paying any in the foreseeable future.
• The company's financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary if the Company is unable to continue as a going concern.
• The company had an accumulated deficit of $30,777,872 as of December 31, 2023.
• The company believes its cash resources will be sufficient to fund operations until the end of the third quarter of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the science behind PT00114 is promising and the company is progressing with clinical trials, the financial situation is concerning with significant losses and a need for additional funding. The risk factors are also substantial, which tempers the overall positive aspects.

Positives

• PT00114 has shown efficacy in preclinical animal models of depression, anxiety, substance abuse, and PTSD.
• The mechanism of action of TCAP suggests it counterbalances stress at the cellular level.
• The company has a strong intellectual property position with exclusive licensing agreements.
• PT00114 has demonstrated a robust safety profile in preclinical studies.
• The company has completed preclinical experiments required to begin a clinical trial.
• The company has a strong scientific advisory board including Dr. Maurizio Fava, a world-leader in psychiatric disorders.
• The company has a basket trial design which offers efficient use of capital in early-stage development.
• The company has a clear strategy for advancing PT00114 through clinical trials and developing additional product candidates.

Negatives

• The company has a history of losses and expects to continue to incur significant operating losses.
• The company has no approved products and has generated no product revenue.
• The company's financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary if the Company is unable to continue as a going concern.
• The company has a limited operating history.
• The company has a high risk of never being profitable.
• The company has limited experience in conducting clinical trials.
• The company relies on third parties for manufacturing and clinical trials.
• The company has no sales, marketing, or distribution capabilities.
• The company's common stock is a Penny Stock subject to specific rules governing its sale to investors that could impact its liquidity.
• The market price of the company's common stock may be volatile.
• The company does not intend to pay dividends for the foreseeable future.

Risks

• The company's financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary if the Company is unable to continue as a going concern.
• The company may not be able to obtain the capital necessary to fund its operations.
• The company's product candidates may not be safe or effective, or receive regulatory approval.
• The company may experience delays or difficulties in the enrollment of subjects to its clinical trials.
• The company relies on third parties to conduct its non-clinical studies and clinical trials.
• The company has no experience in sales, marketing, and distribution.
• The company may not be able to gain market acceptance of its product candidates.
• The company may not be able to manufacture its product candidates in clinical or commercial quantities.
• The company may not be able to maintain its exclusive worldwide license to use and develop PT00114.
• The company's common stock may be delisted if it fails to comply with Nasdaq requirements.
• The company's common stock is a Penny Stock subject to specific rules governing its sale to investors that could impact its liquidity.
• The market price of the company's common stock may be volatile.
• Investors may experience dilution of their ownership interests because of the future issuance of additional shares of the company's common stock.
• The company's common stock is controlled by insiders.
• The company does not intend to pay dividends for the foreseeable future.

Future Outlook

The company aims to rapidly advance PT00114 through clinical trials, develop additional product candidates from the TCAP family, explore efficacy in additional stress-related disorders, build a strong team, and assess strategic partnership opportunities.

Management Comments

• The clinical development program will be led by Dr. Maurizio Fava, MD, PhD, a world-leader in psychiatric disorders.
• We believe the basket trial structure offers the most efficient use of capital in early-stage development and will give us insights into which indication we should focus on in advanced clinical trials.
• We believe this novel mechanism of action can provide an attractive therapeutic profile for patients who are not fully responsive to currently available therapies.

Industry Context

The document highlights the significant unmet need in the treatment of stress-related neuropsychiatric disorders, including depression, anxiety, addiction, and PTSD, and positions Protagenic's TCAP-based therapy as a novel approach to address these conditions. The document also notes that the developmental pipelines are sparse and few novel candidates are in development.

Comparison to Industry Standards

• The document compares PT00114 to existing treatments for TRD, such as opioid receptor modulators, atypical antipsychotics, ketamine, and GABA receptor modulators, highlighting its potential advantages in terms of mechanism of action and side effect profile.
• The document notes that current treatments for GAD, such as SSRIs and SNRIs, have limited efficacy and significant side effects, suggesting a potential market for PT00114.
• The document notes that current treatments for PTSD, such as sertraline and paroxetine, have limited efficacy and significant side effects, suggesting a potential market for PT00114.
• The document notes that current treatments for OUD, such as methadone and buprenorphine, have limited efficacy, high treatment burden, and significant side effects, suggesting a potential market for PT00114.
• The document notes that current treatments for AUD, such as naltrexone and acamprosate, have limited efficacy and high treatment burden, suggesting a potential market for PT00114.

Legal Proceedings

• The company states that from time to time it may be named in claims arising in the ordinary course of business.
• The company states that as of December 31, 2023, no legal proceedings, government actions, administrative actions, investigations or claims are pending against it or involve it that, in the opinion of management, could reasonably be expected to have a material adverse effect on its business, financial condition, and results of operations.

Related Party Transactions

• The company utilizes office space in a conference room of Agenus, Inc. at no cost.
• The company incurred $149,509 and $105,928 in expenses related to research and development services performed by Agenus Inc. during the years ended December 31, 2023 and 2022, respectively.
• The company incurred $106,754 and $105,801 in expenses related to research and development services performed by CTC North, GmbH during the years ended December 31, 2023 and 2022, respectively.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional funding and the volatility of its stock price.
• Employees and consultants may be affected by the company's financial instability and potential need to curtail operations.
• Customers (potential patients) may benefit from the development of new treatments for stress-related disorders, but the timeline for commercialization is uncertain.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding.
• The company's success is dependent on the continued support of its scientific advisors and collaborators.

Next Steps

• The company anticipates re-submitting an investigational new drug (IND) application in advance of initiating the Phase IIa portion of its present clinical study.
• The company anticipates announcing complete results of the single-dose portion of the Phase I trial in the second quarter of 2024.
• The company anticipates commencing the multiple dose portion of the Phase I study for PT00114 in the second quarter of 2024.
• The company anticipates initiating a Phase IIa study for PT00114 in the third quarter of 2024.

Key Dates

Keywords

PT00114, TCAP, neuropsychiatric disorders, clinical trials, depression, anxiety, substance abuse, PTSD, biopharmaceutical, drug development, mental health, stress, University of Toronto, Phase I/II, FDA, licensing agreement, preclinical studies